�Nutra Pharma Corp. (OTCBB: NPHC),
a biotechnology company that is developing drugs for HIV and Multiple
Sclerosis, has announced that its wholly-owned drug discovery
subsidiary, ReceptoPharm, has reported initial positive safety information
from its Phase IIb/IIIa clinical written report of RPI-78M for treating
Adrenomyeloneuropathy (AMN). RPI-78M is ReceptoPharm's leading drug
campaigner for treating neurological and autoimmune disorders.
"Initial reports and feedback from physicians involved with this
clinical study ingest reported that patients have experienced no adverse
side effects from RPI-78M," explained Paul Reid, CEO of ReceptoPharm.
"This is an important indicator of the success of this clinical study,
as it provides the medical and pharmacologic communities with early
grounds supporting the safety of our leading drug candidate,
RPI-78M," he concluded.
Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder
that affects about 30,000 people oecumenical. The disorder is
characterized by the loss of the fatso covering (myelin sheath) on
nerve fibers within the brain (intellectual demyelination) and the
progressive degeneration of the adrenal gland (adrenal atrophy).
Neurological disability in AMN is slowly progressive over several
decades.
AMN interests the wider neurological community because of its
similarities to Multiple Sclerosis (MS). There is currently no
approved treatment for AMN. Additionally, the disease's rarity
designates it as an orphan drug nominee both in Europe and in the
U.S. The Company has applied for Orphan do drugs status in the U.S. and
intends on doing so for the EU.
ReceptoPharm expects to present the fill out clinical findings and
data from this study by the end of September.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the
acquisition, licensing and commercialisation of pharmaceutical
products and technologies for the management of neurological
disorders, cancer, autoimmune and infectious diseases. Nutra Pharma
Corp. through and through its subsidiaries carries out basic drug discovery
inquiry and clinical development and also seeks strategic licensing
partnerships to reduce the risks associated with the drug development
process. The Company's subsidiary, ReceptoPharm, Inc., is developing
these technologies for the production of drugs for HIV and Multiple
Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is
meshed in the research and development of diagnostic test kits
intentional to be used for the rapid identification of infectious
diseases such as Tuberculosis (TB) and Mycobacterium
avium-intracellulare (MAI). Nutra Pharma continues to identify and
acquire rational property and companies in the biotechnology arena.
SEC Disclaimer
This conjure release contains forward-looking statements. The words or
phrases "would be," "will allow," "intends to," "will likely result,"
"ar expected to," "will proceed," "is anticipated," "estimate,"
"project," or similar expressions ar intended to identify
"modern statements." Actual results could differ materially
from those projected in Nutra Pharma's ("the Company") business contrive.
The Company's business is subject to various risks, which ar
discussed in the Company's filings with the Securities and Exchange
Commission ("SEC").� The initial safety data from the clinical study
in Adrenomyeloneuropathy (AMN) should not be construed as an
indication in whatsoever way whatsoever of the value of the Company or its
common stock.� The Company's filings may be accessed at the SEC's
Edgar system at web.sec.gov.� Statements made herein are as of the
date of this press release and should non be relied upon as of whatsoever
subsequent day of the month. The Company cautions readers not to place reliance on
such statements. Unless otherwise compulsory by applicable law, we do
non undertake, and we specifically disclaim whatever obligation, to update
whatever forward-looking statements to reflect occurrences, developments,
unanticipated events or circumstances after the date of such statement.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
More info
